

WEISER MICHAEL  
Form 4  
January 04, 2011

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
WEISER MICHAEL

2. Issuer Name and Ticker or Trading Symbol  
ZIOPHARM ONCOLOGY INC  
[ZIOP]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
12/31/2010

Director  10% Owner  
 Officer (give title below)  Other (specify below)

C/O ZIOPHARM ONCOLOGY, INC., 1180 AVENUE OF THE AMERICAS, SUITE 1920

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

NEW YORK, NY 10036

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
| Common Stock, \$.001 par value  |                                      |  |                                | (A) or (D) Price  | 150,945 <sup>(1)</sup>  | D  |                                   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

Edgar Filing: WEISER MICHAEL - Form 4

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable Expiration Date                         | Title Amount or Number of Shares                              |
| Warrants to Purchase Common Stock          | \$ 4.75  |                                      |  |                                |   | 09/13/2005 05/31/2012                                    | Common Stock, \$0.001 par value 35,566                        |
| Director Stock Option (right to buy)       | \$ 4.31  |                                      |  |                                |   | 07/20/2007 12/22/2014                                    | Common Stock, \$0.001 par value 15,029                        |
| Director Stock Option (right to buy)       | \$ 5.01  |                                      |  |                                |   | 04/26/2006 04/26/2016                                    | Common Stock, \$0.001 par value 15,000                        |
| Warrants to purchase Common Stock          | \$ 5.09  |                                      |  |                                |   | 05/03/2006 05/03/2013                                    | Common Stock, \$0.001 par value 18,319                        |
| Director Stock Option (right to buy)       | \$ 6.49  |                                      |  |                                |   | 12/13/2009 12/13/2016                                    | Common Stock, \$0.001 par value 15,000                        |
| Stock Option (right to buy)                | \$ 4.85  |                                      |  |                                |   | (2) 06/18/2017   | Common Stock 15,000   |
| Stock Option (right to buy)                | \$ 2.73  |                                      |  |                                |   | (3) 12/12/2017   | Common Stock 20,000   |
|  | \$ 0.7   |                                      |  |                                |   | (4) 05/13/2019   | 15,000  |

|                              |         |            |   |        |     |                       |  |                                 |        |
|------------------------------|---------|------------|---|--------|-----|-----------------------|--|---------------------------------|--------|
| Stock Option (right to buy)  |         |            |   |        |     |                       |  | Common Stock                    |        |
| Stock Options (right to buy) | \$ 2.85 |            |   |        | (5) | 12/31/2019            |  | Common Stock, \$ .001 par value | 7,500  |
| Stock Options (right to buy) | \$ 5.09 |            |   |        |     | 03/31/2011 03/31/2020 |  | Common Stock, \$ .001 par value | 15,000 |
| Stock Option (right to buy)  | \$ 4.77 | 12/31/2010 | A | 30,000 | (6) | 12/31/2020            |  | Common Stock                    | 30,000 |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |         |       |
|--|---------------|-----------|---------|-------|
|  | Director      | 10% Owner | Officer | Other |
| WEISER MICHAEL<br>C/O ZIOPHARM ONCOLOGY, INC.<br>1180 AVENUE OF THE AMERICAS, SUITE 1920<br>NEW YORK, NY 10036 |               |           | X       |       |

## Signatures

/s/ Michael Weiser  
01/03/2011

\_\_Signature of Reporting Person                      Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes grants of restricted stock with restrictions that lapsed as to 3,750 shares on December 31, 2010 and restrictions that will lapse as to 15,000 shares on March 31, 2011 and as to 3,750 shares on December 31, 2011.
- (2) 5,000 shares vest on each of 6/18/08, 6/18/09 and 6/18/10.
- (3) 6,667 shares vest on each of 12/12/08 and 12/12/09; 6,666 shares vest on 12/12/10.
- (4) 5,000 shares vest on each of 12/31/09, 6/30/2010 and 12/31/2010.
- (5) 3,750 shares vest on each of 12/31/2010 and 12/31/2011.
- (6) 10,000 shares vest on each of 12/31/2011, 12/31/2012 and 12/31/2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.